Hims & Hers Health Inc. Q3 2025 Earnings Report: Revenue and Subscriber Growth Surpass Expectations
Hims & Hers Health Inc. released its Q3 2025 earnings report, with revenue reaching USD 600 million, surpassing the IBES estimate of USD 579.3 million and marking a 49% year-over-year growth. The company achieved a net income of USD 16 million and an EPS of USD 0.06, despite market expectations of a 44% drop in adjusted EPS. Key focus areas include revenue growth, gross margin execution, and EPS improvement amidst regulatory disruptions. The outlook for the full year includes revenue in the range of USD 2,335-2,355 million and adjusted EBITDA between USD 307-317 million. Additionally, free cash flow remained stable at $79.4 million, and discussions with Novo Nordisk are ongoing for potential offerings pending FDA approval.
0 followers
Login to post
- 🤖📊🚀 Hims & Hers: The Telehealth Titan Rewriting Personalised Health’s Playbook in a GLP-1 World 🚀📊🧠
🤖📊🚀 Hims & Hers: The Telehealth Titan Rewriting Personalised Health’s Playbook in a GLP-1 World 🚀📊🧠
$Hims & Hers Health Inc.(HIMS)$ $Eli Lilly(LLY)$ $Novo-Nordisk A/S(NVO)$ 🎯 Executive Summary I’m convinced Hims & Hers Health (HIMS) isn’t just participating in the GLP-1 boom; it’s engineering a defensible ecosystem around direct-to-consumer personalised care. At $45.46, it’s trading in a consolidation zone that screams opportunity as the GLP-1 obesity wave rewires healthcare economics. Q3 2025 delivered $599 million in revenue (+49 % YoY) and $78.4 million in adjusted EBITDA (+53 % YoY), underscoring tangible operating leverage. Subscribers reached 2.47 million (+21 %), monthly revenue per user rose to $80 (+19 %), and 80 % of users now engage in mu - HIMS' Growth Has a "Sweet Tooth" for Weight Loss. Is a Wegovy Deal Imminent for HIMS?
HIMS' Growth Has a "Sweet Tooth" for Weight Loss. Is a Wegovy Deal Imminent for HIMS?
$Hims & Hers Health Inc.(HIMS)$ delivered strong revenue but faced profitability pressures in its Q3 2025 earnings report. Overall, the performance exceeded market expectations, primarily driven by rapid growth in subscription users and expansion of personalized healthcare services. Revenue surged nearly 50% year-over-year, but net profit declined and EPS fell short of analyst consensus, reflecting underlying challenges in cost control and supply chain management.Despite this, discussions regarding a potential collaboration with $Novo-Nordisk A/S(NVO)$ on Wegovy emerged as a major highlight, potentially signaling a strategic resurgence in the company's weight loss sector. However, caution is warranted
